Venous Thromboembolism in Brain Tumor Patients

2016 ◽  
pp. 215-228 ◽  
Author(s):  
Mohammed Jeraq ◽  
David J. Cote ◽  
Timothy R. Smith
Keyword(s):  
Brain Tumor ◽  
Venous Thromboembolism ◽  
Tumor Patients

Venous Thromboembolism in Brain Tumor Patients

2015 ◽  
Author(s):  
Mohammed Jeraq ◽  
David J. Cote ◽  
Timothy R. Smith
Keyword(s):  
Brain Tumor ◽  
Venous Thromboembolism ◽  
Tumor Patients

scholarly journals Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism

Blood ◽  
2017 ◽  
Vol 129 (13) ◽  
pp. 1831-1839 ◽  
Author(s):  
Julia Riedl ◽  
Matthias Preusser ◽  
Pegah Mir Seyed Nazari ◽  
Florian Posch ◽  
Simon Panzer ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Venous Thromboembolism ◽  
Platelet Aggregation ◽  
High Risk ◽  
Brain Tumors ◽  
Tumor Patients ◽  
Primary Brain Tumors ◽  
Key Points ◽  
Podoplanin Expression ◽  
Very High

Key Points Brain tumor patients have a very high risk of VTE. Podoplanin expression by primary brain tumors induces platelet aggregation and is associated with hypercoagulability and a high risk of VTE.

Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients

2013 ◽  
Vol 131 (2) ◽  
pp. 162-165 ◽  
Author(s):  
Johannes Thaler ◽  
Matthias Preusser ◽  
Cihan Ay ◽  
Alexandra Kaider ◽  
Christine Marosi ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Venous Thromboembolism ◽  
Tissue Factor ◽  
Tissue Factor Expression ◽  
Tumor Patients ◽  
Factor Expression

Venous thromboembolism in brain tumor patients

2016 ◽  
Vol 25 ◽  
pp. 13-18 ◽  
Author(s):  
David J. Cote ◽  
Timothy R. Smith
Keyword(s):  
Brain Tumor ◽  
Venous Thromboembolism ◽  
Tumor Patients

Systematic Review of Safety and Cost-Effectiveness of Venous Thromboembolism Prophylaxis Strategies in Patients Undergoing Craniotomy for Brain Tumor

Neurosurgery ◽  
2017 ◽  
Vol 82 (2) ◽  
pp. 142-154 ◽  
Author(s):  
Hanna Algattas ◽  
Dushyant Damania ◽  
Ian DeAndrea-Lazarus ◽  
Kristopher T Kimmell ◽  
Nicholas F Marko ◽  
...  
Keyword(s):  
Systematic Review ◽  
Brain Tumor ◽  
Venous Thromboembolism ◽  
Cost Effectiveness ◽  
Intracranial Hemorrhage ◽  
Cost Effective ◽  
Number Needed To Treat ◽  
Tumor Patients ◽  
Effective Measure ◽  
Vte Prophylaxis

Abstract BACKGROUND Studies have evaluated various strategies to prevent venous thromboembolism (VTE) in neuro-oncology patients, without consensus. OBJECTIVE To perform a systematic review with cost-effectiveness analysis (CEA) of various prophylaxis strategies in tumor patients undergoing craniotomy to determine the safest and most cost-effective prophylaxis regimen. METHODS A literature search was conducted for VTE prophylaxis in brain tumor patients. Articles reporting the type of surgery, choice of VTE prophylaxis, and outcomes were included. Safety of prophylaxis strategies was determined by measuring rates of VTE and intracranial hemorrhage. Cost estimates were collected based on institutional data and existing literature. CEA was performed at 30 d after craniotomy, comparing the following strategies: mechanical prophylaxis (MP), low molecular weight heparin with MP (MP+LMWH), and unfractionated heparin with MP (MP+UFH) to prevent symptomatic VTE. All costs were reported in 2016 US dollars. RESULTS A total of 34 studies were reviewed (8 studies evaluated LMWH, 12 for MP, and 7 for UFH individually or in combination; 4 studies used LMWH and UFH preoperatively). Overall probability of VTE was 1.49% (95% confidence interval (CI) 0.42-3.72) for MP+UFH, 2.72% [95% CI 1.23-5.15] for MP+LMWH, and 2.59% (95% CI 1.31-4.58) for MP, which were not statistically significant. Compared to a control of MP alone, the number needed to treat for MP+UFH is 91 and 769 for MP+LMWH. The risk of intracranial hemorrhage was 0.26% (95% CI 0.01-1.34) for MP, 0.74% (95% CI 0.09-2.61) for MP+UFH, and 2.72% (95% CI 1.23-5.15) for MP+LMWH, which were also not statistically significant. Compared to MP, the number needed to harm for MP+UFH was 208 and for MP+LMWH was 41. Fifteen studies were included in the final CEA. The estimated cost of treatment was $127.47 for MP, $142.20 for MP+UFH, and $169.40 for MP+LMWH. The average cost per quality-adjusted life-year for different strategies was $284.14 for MP+UFH, $338.39 for MP, and $722.87 for MP+LMWH. CONCLUSION Although MP+LMWH is frequently considered the optimal prophylaxis for VTE risk reduction, our model suggests that MP+UFH is the safest and most cost-effective measure to balance VTE and hemorrhage risks in brain tumor patients at lower risk of hemorrhage. MP+LMWH may be more effective for patients at higher risk of VTE.

Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis

2016 ◽  
Vol 130 (3) ◽  
pp. 561-570 ◽  
Author(s):  
Nasser Alshehri ◽  
David J. Cote ◽  
M. Maher Hulou ◽  
Ahmad Alghamdi ◽  
Ali Alshahrani ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Venous Thromboembolism ◽  
Meta Analysis ◽  
Thromboembolism Prophylaxis ◽  
Tumor Patients ◽  
Venous Thromboembolism Prophylaxis

Prophylaxis of venous thromboembolism in brain tumor patients

1994 ◽  
Vol 22 (2) ◽  
pp. 111-126 ◽  
Author(s):  
Mark G. Hamilton ◽  
Russell D. Hull ◽  
Graham F. Pineo
Keyword(s):  
Brain Tumor ◽  
Venous Thromboembolism ◽  
Tumor Patients
Sign in / Sign up

Export Citation Format

Share Document